ArticleStructural heart : the journal of the Heart Team2025
Outcomes After Transcatheter Aortic Valve Replacement Among Medicare Beneficiaries: The Impact of Frailty and Social Vulnerability.
Article in Structural heart : the journal of the Heart Team, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patterns and Timing of Sequential Transcatheter Valve Interventions After Index TAVR, M-TEER, and TMVR: A Nationwide Medicare Analysis.Structural heart : the journal of the Heart Team · 2026Article
- Early Postrranscatheter Aortic Valve Replacement Heart Failure Hospitalization and Outcomes in Older Patients.Journal of the American Heart Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is an accepted alternative to surgery in many patients with severe aortic stenosis. Clinical trials have evaluated early and late outcomes in selected TAVR patients, but predictors of late mortality have been less well studied in a broadly inclusive, national patient cohort undergoing TAVR. We sought to characterize 5-year outcomes after TAVR in Medicare beneficiaries and to evaluate the incremental predictive value of demographics, comorbidities, procedural factors, frailty, and social vulnerability in determining late mortality risk. Methods: We studied the fee-for-service Centers for Medicare & Medicaid Services MedPAR database that includes patients aged ≥65 years undergoing TAVR between 2017 and 2022. The primary endpoint was 5-year mortality. Sequential multivariable Cox models were constructed, incrementally adjusting for demographics, comorbidities, procedural and hospital characteristics, and frailty and social vulnerability. Model performance was assessed using C-statistics and integrated discrimination improvement (IDI). Results: A total of 371,248 TAVR patients were included in the analysis. The baseline model, including only demographic factors (age, sex, and race), yielded modest model performance (C = 0.589). Inclusion of comorbidities improved the model discrimination substantially (C = 0.684; IDI +6.9%, Conclusions: In this large national cohort, frailty and social vulnerability significantly improved risk prediction for long-term mortality after TAVR. We conclude that sociodemographic and frailty-related factors are important components for prediction of 5-year mortality after TAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.